Is the mRNA Influenza Vaccine More Efficacious in Older Adults?

A study published in the New England Journal of Medicine indicates that the mRNA-1010 influenza vaccine is more effective than standard vaccines for adults aged 50 and older. The data shows higher efficacy rates in older demographics, who face a disproportionately high risk of severe illness and death from the flu.
Why it matters
Improving vaccine efficacy for older adults is critical for reducing the significant annual burden of influenza-related hospitalizations and mortality.
In a study published earlier this year in the New England Journal of Medicine, the mRNA-1010 mRNA influenza vaccine prevented disease in adults 50 years and older more effectively than standard vaccines. Specifically, data showed that confirmed influenza-like illness occurred in 2.0% of mRNA-1010 vaccine recipients and 2.8% of comparator recipients, with a relative vaccine efficacy of 26.6% (95% CI, 16.7 to 35.4). And in adults 65 and older, the results were slightly better, with a relative vaccine efficacy of 27.4%.¹
“mRNA-1010 was superior to standard-dose licensed vaccines for prevention of RT-PCR–confirmed, protocol-defined influenza-like illness in adults 50 years of age or older,” the authors concluded.
Influenza Disease Burden in Older Adults
Get smarter about the news
Sign up free for a feed built around what you actually care about, Dive Deeper research on any story, and the full text of every article.
Create free accountAlready have an account? Sign in